In Lupus (SLE) pathogenic (immune complex forming) IgG autoantibodies to nuclear autoantigens are produced with help from autoimmune T helper (Th), Th1 and Th17->TFH cells that also infiltrate kidneys. Although professional APCs are active in presenting autoantigens as disease progresses, it is important to identify which APCs are critical in the initial priming of autoimmune Th cells. Unexpectedly, we found that Lineage- (Lin-) CD117+ (c-Kit+) CX3CR1- (Cx-) cells in lupus splenocytes depleted of known APCs, were most proficient in processing and presenting nuclear autoantigen particles from apoptotic cells to induce autoimmune Th17 responses in lupus prone SNF1 and BL6.Sle mice. The autoimmune Th17 inducers in Lin-c- Kit+CX3CR1- splenocytes were c-Kit+CD41+CD151+ with properties of megakaryocyte (MkP) and/or bipotent megakaryocyte/erythroid progenitors (MEP) of bone marrow, hence the new APC are called M&M cells here. The M&M APC produce requisite cytokines for Th17, but they require contact for optimal Th17 induction upon nucleosome feeding, and can do so only before undergoing differentiation to become c-Kit-CD41+ cells. The M&M APC are increased up to 50 fold in mice and 10 fold in humans with lupus;and they accelerate lupus on transfer in vivo. By gene profiling, we have found select molecules expressed by M&M cells that might be targeted to prevent nuclear autoantigen presentation. Our major hypothesis is that a new category of APC, M&M cells, that efficiently present nuclear autoantigens to induce autoimmune Th17 without requiring Th17- polarizing conditions, use novel molecular pathways for their pathogenic function, and have signature molecules and growth factor requirements that could be targeted to block the autoimmunity generating process. We will accomplish following objectives in 3 years:
Aim 1 : Define molecular mechanisms by which M&M cells induce and expand Th17 cells;Target M&M signature molecules for lupus therapy;Define prevalence of M&M cells in other mouse models of lupus;Determine if they can break tolerance in normal mice, inducing Th17 skewing in response to foreign and self antigens;and characterize M&M's role in Human lupus.
Aim 2 : Study the impact of M&M cells on B cell tolerance and autoimmunity. The studies will substantially advance understanding of lupus pathogenesis and Th17 differentiation biology by characterizing a novel category of APC, determining whether these cells can be a new biomarker for lupus, or a target for lupus therapy by targeting/blocking the initial steps in the generation of autoimmunity.

Public Health Relevance

Systemic Lupus Erythematosus (SLE or lupus), like rheumatoid arthritis, is a major autoimmune disease affecting more commonly women of child bearing age. Lupus patients produce pathogenic (disease causing) antibodies that form immune complexes and bind to normal tissue constituents. This causes severe inflammation and damage to kidneys, blood cells, joints, skin, blood vessels and brain. Although a special population of autoimmune T helper (Th1 and Th17) cells is essential for driving the B cells of lupus to produce pathogenic autoantibodies, the exact cause of lupus is unknown. In this proposal, we will determine how a novel antigen-presenting cell (APC) population initiates breakdown of tolerance to nuclear antigens to induce pathogenic T helper responses in lupus, and how this priming step can be blocked. Overall, understanding molecular and functional mechanism/s of the unusual and potent APC will be of therapeutic value in a broad spectrum of immune mediated diseases in addition to Lupus, such as, Rheumatoid arthritis, Crohn's disease, Psoriasis Multiple Sclerosis, and Autoimmune Diabetes.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Arthritis, Connective Tissue and Skin Study Section (ACTS)
Program Officer
Johnson, David R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Zhang, Li; Bertucci, Anne M; Ramsey-Goldman, Rosalind et al. (2013) Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clin Immunol 149:365-78
Kang, Hee-Kap; Chiang, Ming-Yi; Liu, Michael et al. (2011) The histone peptide H4 71-94 alone is more effective than a cocktail of peptide epitopes in controlling lupus: immunoregulatory mechanisms. J Clin Immunol 31:379-94
Datta, Syamal K (2009) Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheumatol 5:80-2
Kang, Hee-Kap; Ecklund, Diane; Liu, Michael et al. (2009) Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res Ther 11:R59
Xu, Luting; Zhang, Li; Bertucci, Anne M et al. (2008) Apigenin, a dietary flavonoid, sensitizes human T cells for activation-induced cell death by inhibiting PKB/Akt and NF-kappaB activation pathway. Immunol Lett 121:74-83
Zhang, Li; Bertucci, Anne M; Smith, Kimberly A et al. (2007) Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum 56:4132-41
Kang, Hee-Kap; Liu, Michael; Datta, Syamal K (2007) Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 178:7849-58
Kang, Hee-Kap; Datta, Syamal K (2006) Regulatory T cells in lupus. Int Rev Immunol 25:5-25
Kang, Hee-Kap; Michaels, Marissa A; Berner, Beate R et al. (2005) Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 174:3247-55
Datta, Syamal K; Zhang, Li; Xu, Luting (2005) T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens. J Mol Med 83:267-78

Showing the most recent 10 out of 24 publications